TriangleLenvatinib + Pembrolizumab + RT (NCT05603910)
Lenvatinib + Pembrolizumab + RT trial for Recurrent or Unresectable pMMR Endometrial (Uterine) Cancer (NCT05603910). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with endometrial cancer that has come back or cannot be removed with surgery, and whose tumors are mismatch repair proficient.
The idea: combine pembrolizumab, an immunotherapy given by vein, and lenvatinib, a daily pill, with a shorter course of pelvic radiation. The lenvatinib dose is adjusted in steps to find a safe dose.
The study looks at whether this combination is feasible and safe.
This phase 1 study plans 18 patients. At the University of Miami, Aaron Wolfson leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.